Parks! America (OTC:PRKA), an operator of three regional safari parks in Georgia, Missouri, and Texas, reported earnings for its fiscal third quarter on August 8, 2025, with income before income taxes (GAAP) rising more than tenfold versus the prior year, due to the absence of one-time legal expenses. The company posted revenue of $3.48 million. There were no available Wall Street analyst estimates for direct comparison, but saw a marked decline in cash reserves.

Parks! America operates three safari parks positioned near Atlanta, Springfield, and Houston. These safari parks provide drive-through wildlife experiences featuring a variety of animals, appealing to families and school groups seeking close-up encounters with exotic and domestic species. The company rarely imports animals, focusing instead on efficient herd management and domestic acquisitions.

Growth has come from acquiring regional properties. The company’s ability to manage seasonal revenue patterns, maintain operational efficiency, and invest in park experiences are all key to success. Its animal management program, including inter-park animal relocation, supports healthy herds and visitor appeal.

Continue reading

Edesa Biotech (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-related diseases, released its fiscal third quarter results on August 8, 2025, covering the period ended June 30, 2025. The company reported a GAAP EPS loss of $(0.25), outperforming the $(0.26) consensus estimate by $0.01, or 3.8% (GAAP). Revenue (GAAP) remained at $0, matching expectations and consistent with its pre-commercial status. Operating expenses (GAAP) held steady year over year, and Net loss (GAAP) was nearly unchanged. At June 30, 2025, Edesa had cash and cash equivalents of $12.4 million. Overall, the period was marked by stable financials, careful spending, and focused progress on its lead clinical assets.

Source: Analyst estimates for the quarter provided by FactSet.

Edesa Biotech is a biopharmaceutical firm dedicated to developing new therapies for conditions with significant unmet medical needs. Its core strategy centers on immune and inflammatory diseases, targeting indications where existing treatments fall short. These include dermatological and respiratory diseases.

Continue reading

Calidi Biotherapeutics (NYSEMKT:CLDI), a biotechnology company developing stem cell-based and enveloped virus platforms for cancer therapy, released its second quarter 2025 results on August 8, 2025. The most notable news was a net loss attributable to common stockholders of $5.7 million (GAAP), or $(1.99) per share (GAAP), slightly worse than analyst expectations of $(1.92) per share (GAAP). Despite narrowing losses compared to the prior year and continued progress in its pipeline, the period highlighted persistent funding needs and a significant reduction in available cash. The quarter showed incremental operational improvements but underscored ongoing development-stage risks typical of clinical-stage biotech firms.

Source: Analyst estimates for the quarter provided by FactSet.

Calidi Biotherapeutics is focused on developing novel cancer treatments using stem cell-based delivery systems and enveloped virus platforms. The company’s strategy is to leverage allogeneic stem cells, which are donor-derived and can be used for any patient, to enhance the effectiveness of oncolytic viruses. This approach is designed to shield therapeutic viruses from immune clearance, improve their delivery to tumor sites, and trigger immune system attacks against cancer.

Continue reading

Core Scientific (NASDAQ:CORZ), a digital infrastructure provider with roots in bitcoin mining, reported its Q2 FY2025 results on August 8, 2025. The report revealed a mixed performance. The company posted a net loss, largely due to non-cash charges, as GAAP revenue dropped to $78.6 million, missing analyst expectations of $83.8 million (GAAP). This represented a 44.3% year-over-year decline. The results reflected continued pressure in Core Scientific’s legacy bitcoin mining operations, only partly offset by growing, though still modest, revenue from its newer colocation and AI computing business. Overall, the quarter underscored both the ongoing costs of transition and some encouraging early growth in new digital infrastructure services.

Source: Analyst estimates provided by FactSet. Management expectations based on management’s guidance, as provided in Q1 2025 earnings report.

Core Scientific operates purpose-built facilities for digital asset mining (such as bitcoin) and high-density colocation, also known as hosting services for demanding computing needs like artificial intelligence. Historically, the company earned most of its revenue by directly mining bitcoin using fleets of specialized computers known as application-specific integrated circuits (ASICs).

Continue reading

Interpace Biosciences (OTC:IDXG), a molecular diagnostics company specializing in thyroid cancer risk assessment and other oncology tests, announced its earnings for the second quarter of fiscal 2025 on August 8, 2025. The headline news: a sharp revenue decline to $9.2 million (GAAP) in the wake of losing insurance reimbursement for its PancraGEN® pancreatic cancer test, partially mitigated by record performance in its thyroid diagnostics segment. Profitability fell versus last year, with gross margin (GAAP) slipping to 57% and the company moving to an operating loss of $0.5 million. Performance missed the prior-year period but highlighted a stabilizing core in thyroid diagnostics. No analyst consensus or external estimate comparison was available for this period.

Interpace Biosciences develops and commercializes molecular diagnostic tests aimed at cancer risk assessment, particularly thyroid and pancreatic conditions. Its key products are ThyGeNEXT®, a next-generation sequencing (NGS) assay for thyroid nodules, and ThyraMIR®v2, a microRNA panel that uses an algorithm to classify thyroid cancer risk. The company previously offered PancraGEN®, a molecular test for pancreatic cancer risk, but this line has now been discontinued due to reimbursement loss. Interpace also offers RespriDX® (lung cancer origin differentiation) and is developing BarreGEN® for Barrett’s Esophagus.

The business is now focused exclusively on the thyroid diagnostics segment, reflecting a strategic shift. Success now primarily depends on growing adoption of thyroid test offerings and improving lab operational efficiency through investments in artificial intelligence (AI) and automation technologies.

Continue reading

Skechers (NYSE:SKX), a global footwear and apparel designer known for its focus on comfort and innovation, released its results for the second quarter of fiscal 2025 on August 8, 2025. GAAP revenue was $2.44 billion, a 13.1% increase in GAAP sales from the prior year. Non-GAAP revenue of $2,410.0 million surpassed the analyst estimate of $2,351.54 million. Non-GAAP earnings per share matched the expected $0.83. However, the period highlighted declining margins, with gross margin falling to 53.3% from 54.9% (GAAP) and operating margin (GAAP) down to 7.1% versus 9.6% last year. Overall, the quarter reflected robust international growth and expanding direct-to-consumer sales, but ongoing margin pressure and cost challenges.

Source: Analyst estimates for the quarter provided by FactSet.

Skechers designs, develops, and markets a diverse range of footwear, apparel, and accessories, aiming to deliver both style and comfort. Its products target an international audience and include proprietary comfort technologies such as Hands Free Slip-ins (shoes that allow the wearer to step in without using hands), Arch Fit insoles (specialist insoles for support), and Air-Cooled Memory Foam (cushioning systems). The company splits its distribution between Wholesale — selling to third-party retailers — and Direct-to-Consumer channels, which include company-owned stores and branded websites.

Continue reading

Phunware (NASDAQ:PHUN), a developer of mobile software and cloud-based application platforms, reported its Q2 2025 earnings on August 8, 2025. The quarter was marked by significant revenue decline and a wide miss versus analyst estimates, with GAAP revenue of $0.4 million, missing the analyst estimate of $0.73 million by 44.9%. Revenue (GAAP) dropped to $0.455 million compared to expectations of $0.7265 million, while the net loss (GAAP) reached $3.14 million. Despite the poor top-line performance, Phunware recorded an improved gross margin of 43.9% and continued to invest in new technologies, particularly artificial intelligence features. The overall quarter revealed ongoing challenges, with new product initiatives yet to make a financial impact.

Source: Analyst estimates provided by FactSet.

Phunware creates cloud-based software platforms for mobile applications, focusing on industries such as hospitality and healthcare. Its framework allows customers to build, manage, and monetize branded mobile experiences tailored to specific needs. A core differentiator is its long-standing expertise in vertical mobile apps, and its approach centers on providing a seamless consumer journey and actionable data insights.

Continue reading

Westwood Group (NYSE:WHG), an asset management firm focused on investment advisory services and innovative investment products, reported its second quarter 2025 earnings on August 8, 2025. Westwood highlighted higher net income (GAAP) and improved assets under management during Q2 2025, while GAAP revenue showed only a modest year-over-year increase. There were no published analyst estimates to compare actual results against expectations. GAAP revenue reached $23.1 million, non-GAAP economic earnings per share climbed to $0.32, and Net income (GAAP) swung to $1.0 million from a $2.2 million loss in Q2 2024. Overall, the quarter represents meaningful operational progress, particularly in profitability and asset growth, though topline expansion remains limited.

Westwood Group operates as a diversified investment management company. The business manages assets for institutional clients, intermediaries, and wealth management clients. Its revenue is primarily generated by fees based on the size of assets it manages, also known as assets under management (AUM).

The company’s approach centers on organic AUM growth, product innovation, and distribution expansion. Key success factors include effective client relationship management, launching new investment products such as exchange-traded funds (ETFs), and maintaining strong operational and regulatory compliance. Notably, Westwood targets organic flows as well as new mandates, and leverages acquisitions to diversify both its revenue and client base.

Continue reading

Global Self Storage (NASDAQ:SELF), a self-storage real estate investment trust (REIT) operating across the U.S, announced its financial results for the quarter ended June 30, 2025, on August 8, 2025. Global Self Storage delivered $3.19 million in GAAP revenue, beating analysts’ estimates of $3.05 million, and reported GAAP diluted earnings per share of $0.06, compared to $0.05 for Q2 2024. Same-store Net Operating Income (NOI), a non-GAAP measure, increased 4.0%, while occupancy and average tenant duration reached new highs. The quarter demonstrated stability and operational efficiency, although growth in revenue and portfolio size remained measured given industry competition and a lack of new acquisitions.

Source: Analyst estimates for the quarter provided by FactSet.

Global Self Storage owns and manages self-storage facilities, providing storage solutions to residential and commercial customers. The company holds a portfolio of 12 same-store locations and manages one third-party property across eight U.S. states. It operates as a REIT, which means it must meet specific regulatory requirements and distribute most of its earnings to shareholders via dividends.

Continue reading

Exicure (NASDAQ:XCUR), a biotechnology company that recently pivoted its business model following the acquisition of GPCR Therapeutics USA Inc, reported its second quarter 2025 earnings on August 8, 2025. The main headlines from this release included another quarter of no reported revenue and a steeper net loss of $2.6 million (GAAP), combined with a clear warning from management about the need for near-term financing to continue business operations. There were no Wall Street consensus estimates available for comparison. Overall, the quarter underscored significant operational challenges and funding constraints, even as the company began to integrate newly acquired assets and expand its research pipeline.

Exicure is a clinical-stage biotechnology company undergoing a major transition. Historically, the company aimed to create therapies using its unique Spherical Nucleic Acid (SNA) platform.

With the acquisition of GPCR Therapeutics USA Inc. Exicure is now focused on developing therapeutics for hematologic diseases—disorders affecting blood and bone marrow. The lead pipeline program aims to improve stem cell mobilization, particularly in diseases like multiple myeloma (a type of blood cancer), sickle cell disease, and areas related to cell and gene therapy. Critical success factors now hinge upon securing new financing, executing new business deals, and leveraging existing intellectual property for potential future licensing revenue.

Continue reading

Bitcoin Magazine

Will America Become the Bitcoin and Crypto Capital of the World? Here’s an Expert’s Take.

In the wake of the Tornado Cash verdict and the Samourai Wallet developers’ plea deal, Peter Van Valkenburgh, executive director of Coin Center, a nonprofit organization focused on Bitcoin and crypto policy issues, believes that President Trump’s vision of making the United States the crypto capital of the world might not be truly fulfilled.

This post Will America Become the Bitcoin and Crypto Capital of the World? Here’s an Expert’s Take. first appeared on Bitcoin Magazine and is written by Frank Corva.

Bitcoin Magazine

Know-Your-Customer: The Quiet Kill Switch

The know-your-customer (KYC) threat isn’t coming. It’s already here, and it didn’t arrive through a nationwide ban or an emergency executive order. It quietly showed up with a checkbox and a Terms of Service agreement. While the influencers make noise about CBDCs and paper bitcoin, the real control system has already been deployed: Know Your […]

This post Know-Your-Customer: The Quiet Kill Switch first appeared on Bitcoin Magazine and is written by Ghost Ghost.

Bitcoin Magazine

Bitcoin Price Stays About $115,000 As Spain’s Banking Giant BBVA Partners With Binance To Provide Custody

Bitcoin price held steady above $115,000 as Financial Times reveals Binance partners with Spain’s BBVA bank to provide third-party custody services, allowing customers to store assets in U.S. Treasury securities. The move aims to rebuild trust following Binance’s $4.3 billion regulatory settlement in 2023, with BBVA acting as an independent custodian to ensure greater security of customer funds.

This post Bitcoin Price Stays About $115,000 As Spain’s Banking Giant BBVA Partners With Binance To Provide Custody first appeared on Bitcoin Magazine and is written by Vivek Sen.

Bitcoin Magazine

This Bitcoin ETF Strategy Has Outperformed BTC Buy-and-Hold

Discover how a Bitcoin ETF flow strategy has delivered stronger returns than BTC buy-and-hold, leveraging institutional trading patterns.

This post This Bitcoin ETF Strategy Has Outperformed BTC Buy-and-Hold first appeared on Bitcoin Magazine and is written by Matt Crosby.

Court documents showed there was at least one 90-year-old, and some people had “set in stone” their opinions about the Tornado Cash co-founder’s criminal charges.

A bullish regulatory tailwind is forming as the SEC clarifies its stance on crypto, liquid staking and tokenization — with institutional investors and IPOs responding in kind.

Four state-level lawsuits against three celebrities and individuals tied to the EMAX token may proceed after a California judge’s ruling.

Donations to the embattled software developer increased after Wednesday’s partial verdict and the possibility of a retrial.

Ukraine has had some regulatory starts and stops when it comes to crypto, though momentum for a regulatory bill has picked up since 2024.

Bitcoin could challenge the $120,000 to $123,218 resistance zone but crossing it may be a tough ask for the bulls.

Ether taps $4,000 for the first time in eight months in a further win for ETH bulls and the broader altseason, while Bitcoin dominance fades.

Web3 AI projects often force blockchain integration to access capital, harming innovation by prioritizing ecosystem compatibility over practical AI solutions.